| 1 | advocacy partners investors press | | | | | | | 2 | 0.98% |
| 2 | nephropathy atrasentan zigakibart bion1301 | | | | | | | 2 | 0.98% |
| 3 | opportunities life at chinook | | | | | | | 2 | 0.98% |
| 4 | job opportunities life at | | | | | | | 2 | 0.98% |
| 5 | partners investors press releases | | | | | | | 2 | 0.98% |
| 6 | about us overview purposevalues | | | | | | | 2 | 0.98% |
| 7 | us overview purposevalues pipeline | | | | | | | 2 | 0.98% |
| 8 | overview purposevalues pipeline pipeline | | | | | | | 2 | 0.98% |
| 9 | purposevalues pipeline pipeline iga | | | | | | | 2 | 0.98% |
| 10 | team spotlights job opportunities | | | | | | | 2 | 0.98% |
| 11 | our team spotlights job | | | | | | | 2 | 0.98% |
| 12 | join our team spotlights | | | | | | | 2 | 0.98% |
| 13 | spotlights job opportunities life | | | | | | | 2 | 0.98% |
| 14 | atrasentan zigakibart bion1301 chk336 | | | | | | | 2 | 0.98% |
| 15 | zigakibart bion1301 chk336 research | | | | | | | 2 | 0.98% |
| 16 | bion1301 chk336 research and | | | | | | | 2 | 0.98% |
| 17 | us join our team | | | | | | | 2 | 0.98% |
| 18 | join us join our | | | | | | | 2 | 0.98% |
| 19 | discovery scientific publications patients | | | | | | | 2 | 0.98% |
| 20 | scientific publications patients clinical | | | | | | | 2 | 0.98% |
| 21 | publications patients clinical trials | | | | | | | 2 | 0.98% |
| 22 | patients clinical trials patient | | | | | | | 2 | 0.98% |
| 23 | investors press releases financialsfilings | | | | | | | 2 | 0.98% |
| 24 | resources advocacy partners investors | | | | | | | 2 | 0.98% |
| 25 | kidney disease at the | | | | | | | 1 | 0.49% |
| 26 | disease at the 60th | | | | | | | 1 | 0.49% |
| 27 | at the 60th european | | | | | | | 1 | 0.49% |
| 28 | association era congress june | | | | | | | 1 | 0.49% |
| 29 | terms of use privacy | | | | | | | 1 | 0.49% |
| 30 | contact terms of use | | | | | | | 1 | 0.49% |
| 31 | renal association era congress | | | | | | | 1 | 0.49% |
| 32 | in chronic kidney disease | | | | | | | 1 | 0.49% |
| 33 | era congress june 17 | | | | | | | 1 | 0.49% |
| 34 | chronic kidney disease at | | | | | | | 1 | 0.49% |
| 35 | use privacy policy © 2024 | | | | | | | 1 | 0.49% |
| 36 | repair in chronic kidney | | | | | | | 1 | 0.49% |
| 37 | failed repair in chronic | | | | | | | 1 | 0.49% |
| 38 | of failed repair in | | | | | | | 1 | 0.49% |
| 39 | role of failed repair | | | | | | | 1 | 0.49% |
| 40 | of use privacy policy | | | | | | | 1 | 0.49% |